A Study to Evaluate the Effects of NST-4016 on QT/Corrected QT (QTc) Interval
Status:
Completed
Trial end date:
2018-09-24
Target enrollment:
Participant gender:
Summary
This is a Phase 1, single centre, randomised, double blind (except for moxifloxacin), placebo
and positive controlled, 4 way crossover study assessing the ECG effects of therapeutic and
supratherapeutic doses of icosabutate in healthy male and female subjects.
Phase:
Phase 1
Details
Lead Sponsor:
NorthSea Therapeutics B.V.
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination